Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Q3 2025 value amounting to $1.0 million.

  • Ironwood Pharmaceuticals' Current Deferred Revenue changed N/A to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year change of. This contributed to the annual value of $2.0 million for FY2024, which is 2244.27% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Current Deferred Revenue stood at $1.0 million for Q3 2025.
  • Ironwood Pharmaceuticals' 5-year Current Deferred Revenue high stood at $2.6 million for Q4 2023, and its period low was $978000.0 during Q2 2025.
  • Moreover, its 3-year median value for Current Deferred Revenue was $1.8 million (2025), whereas its average is $1.7 million.
  • Data for Ironwood Pharmaceuticals' Current Deferred Revenue shows a peak YoY increase of 2244.27% (in 2024) and a maximum YoY decrease of 2244.27% (in 2024) over the last 5 years.
  • Quarter analysis of 3 years shows Ironwood Pharmaceuticals' Current Deferred Revenue stood at $2.6 million in 2023, then fell by 22.44% to $2.0 million in 2024, then tumbled by 48.43% to $1.0 million in 2025.
  • Its Current Deferred Revenue stands at $1.0 million for Q3 2025, versus $978000.0 for Q2 2025 and $1.8 million for Q1 2025.